The diabetes treatment developer, which counts WL Gore and Johnson & Johnson as investors, has raised a further $27m for its latest round.
ViaCyte, a US-based diabetes treatment developer backed by advanced materials manufacturer WL Gore and healthcare product supplier Johnson & Johnson, has added $27m to a series D round that now totals $107m.
The new funding came from Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital, as well as TPG Capital, RA Capital Management, Sanderling Ventures and unnamed private investors. The other $80m came from the same backers across two tranches and was disclosed in late…
